Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Total Non-Current Liabilities (2020 - 2022)

Caribou Biosciences (CRBU) reported Total Non-Current Liabilities of $72.9 million for Q4 2022, up 33.72% year-over-year from $54.5 million in Q4 2021, and down 2.43% on a QoQ basis from $74.7 million in Q3 2022.

Caribou Biosciences (CRBU) has 3 years of Total Non-Current Liabilities data on file, last reported at $72.9 million in Q4 2022.

  • Quarterly Total Non-Current Liabilities rose 33.72% year-over-year to $72.9 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $72.9 million (up 33.72% YoY) and the FY2022 annual result came in at $72.9 million, up 33.72% from the prior year.
  • Total Non-Current Liabilities eased to $72.9 million in Q4 2022 per CRBU's latest filing, from $74.7 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $74.7 million in Q3 2022 and bottomed at $18.0 million in Q4 2020.
  • The 3-year median for Total Non-Current Liabilities is $65.1 million (2021), against an average of $60.1 million.
  • The widest annual swing landed in 2021, when Total Non-Current Liabilities jumped 203.12%; it then soared 30.14% in 2022.
  • Tracing CRBU's Total Non-Current Liabilities over 3 years: stood at $18.0 million in 2020, then jumped by 203.12% to $54.5 million in 2021, then surged by 33.72% to $72.9 million in 2022.
  • Per Business Quant, the three latest CRBU Total Non-Current Liabilities figures stand at $72.9 million (Q4 2022), $74.7 million (Q3 2022), and $73.5 million (Q2 2022).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 11.03 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - 42,980.09
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 95.20 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - 110.28 Mn
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 5.87 Bn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 7.32 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 4.05 Bn
10 Caribou Biosciences 232.46 Mn 114.84 Mn - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2022 72.89 Mn
Sep 30, 2022 74.71 Mn
Jun 30, 2022 73.48 Mn
Mar 31, 2022 74.19 Mn
Dec 31, 2021 54.51 Mn
Sep 30, 2021 57.41 Mn
Jun 30, 2021 55.78 Mn
Dec 31, 2020 17.98 Mn